Log in to your Inderes Free account to see all free content on this page.
Faron Pharmaceuticals
1.85 EUR
-3.95 %
5,530 following
FARON
First North Finland
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
-3.95 %
-14.84 %
-16.00 %
-30.79 %
-27.24 %
-9.63 %
-53.80 %
-40.58 %
-46.90 %
Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.
Read moreMarket cap
219.1M EUR
Turnover
1.06M EUR
P/E (adj.) (25e)
EV/EBIT (adj.) (25e)
P/B (25e)
EV/S (25e)
Dividend yield-% (25e)
Revenue and EBIT-%
Revenue K
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
4.3.
2026
Annual report '25
30.3.
2026
General meeting '26
26.8.
2026
Interim report Q2'26
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types
Faron drew down the second tranche of the convertible bond
Faron issues second tranche of bonds with an aggregated principal amount of EUR 10 million under its convertible bond arrangement
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
